pubmed-article:17988304 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C1521726 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0205219 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C0278348 | lld:lifeskim |
pubmed-article:17988304 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
pubmed-article:17988304 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:17988304 | pubmed:dateCreated | 2007-11-8 | lld:pubmed |
pubmed-article:17988304 | pubmed:abstractText | To date little data exist about treatment of hematologic malignancies in patients with end-stage renal disease (ESRD). While administration of immunochemotherapy comprising the CD20-antibody rituximab is a well-established treatment strategy in patients with normal renal function, little information on safety and efficacy is available in the setting of ESRD. Here we describe for the first time a hemodialysis patient suffering from diffuse large B-cell Non-Hodgkin's lymphoma (DLBCL) who was treated with polychemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in combination with rituximab (R-CHOP). We observed no major adverse events and treatment resulted in a partial remission of the DLBCL. Thus, administration of R-CHOP may be considered as a safe therapeutic option in this setting. Of note, this patient had a previous history of hairy cell leukemia. A review of the literature was performed and the potential etiologic link of these two B-cell malignancies is discussed in the light of available information. | lld:pubmed |
pubmed-article:17988304 | pubmed:language | eng | lld:pubmed |
pubmed-article:17988304 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17988304 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17988304 | pubmed:month | Dec | lld:pubmed |
pubmed-article:17988304 | pubmed:issn | 1751-5521 | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:FeldmannGG | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:GerhardsUU | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:WoitasRR | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:SpenglerUU | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:NattermannJJ | lld:pubmed |
pubmed-article:17988304 | pubmed:author | pubmed-author:NähleC PCP | lld:pubmed |
pubmed-article:17988304 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17988304 | pubmed:volume | 29 | lld:pubmed |
pubmed-article:17988304 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17988304 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17988304 | pubmed:pagination | 469-73 | lld:pubmed |
pubmed-article:17988304 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:meshHeading | pubmed-meshheading:17988304... | lld:pubmed |
pubmed-article:17988304 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17988304 | pubmed:articleTitle | Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. | lld:pubmed |
pubmed-article:17988304 | pubmed:affiliation | Department of Internal Medicine 1, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany. gfeldma4@jhmi.edu | lld:pubmed |
pubmed-article:17988304 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17988304 | pubmed:publicationType | Review | lld:pubmed |
pubmed-article:17988304 | pubmed:publicationType | Case Reports | lld:pubmed |